Wedbush Remains Bullish on MannKind Corporation (MNKD)
MannKind Corporation (NASDAQ:MNKD) is one of the 13 Stocks Under $5 With High Upside Potential.
Insider Monkey Blog
Leerink Partners Reiterates a Buy Rating on Geron Corporation (GERN)
Geron Corporation (NASDAQ:GERN) is one of the 13 Stocks Under $5 With High Upside Potential.
Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Stocks Under $5 With High Upside Potential. ImmunityBio Inc.
Hedge Fund Investor Letters Q1 2025
We will be sharing Q1 2025 hedge fund investor letters in this article.
Here are Rogue Funds’ Comments on Costco (COST)
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
BILL Holdings (BILL) Fell due to Weakness in Consumer Confidence
Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter 2025 investor letter.
Should You Hold Achieve Life Sciences (ACHV)?
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Rogue Funds’ New Holding: Biotricity (BTCY)
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
12 Best Stagflation Stocks to Buy Now
There’s a particular discomfort that comes with watching an economy slow down while prices keep climbing.
Here’s Why ASP Isotopes (ASPI) Shares Re-rated Positively in Q1
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Rogue Funds’ Q1 2025 Investor Letter
Rogue Funds, an investment management company, released its first quarter 2025 investor letter. The fund depreciated 12.4% net of fees in the quarter.
Here’s What Boosted Tempus AI (TEM) in Q1
Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter 2025 investor letter.
AMG Frontier Small Cap Growth Fund Established a Position in CACI International Inc (CACI) in Q1
Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter 2025 investor letter.
Here’s AMG Frontier Small Cap Growth Fund’s Comment on FTAI Aviation Ltd. (FTAI)
Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter 2025 investor letter.
Is Ultra Clean Holdings (UCTT) Well Positioned to Increase Its Market Share Over the Long Term?
Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter 2025 investor letter.
indie Semiconductor (INDI) Sold Off in Q1 Due to Tariff Uncertainty
Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter 2025 investor letter.
AMG Frontier Small Cap Growth Fund’s Q1 2025 Investor Letter
Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter 2025 investor letter.
Here’s Why Penn Davis McFarland Sold Fortrea Holdings (FTRE) in Q1
Penn Davis McFarland, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Sprouts Farmers Market (SFM): Penn Davis McFarland’s Outstanding Performer in Q1
Penn Davis McFarland, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Penn Davis McFarland’s Q1 2025 Investor Letter
Penn Davis McFarland, an investment management company, released its first quarter 2025 investor letter. Decades of unchecked government spending have strained the U.S.
Marsh & McLennan Companies (MMC) Shares Fell in Q2. Here’s Why
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2025 investor letter.
Thermo Fisher Scientific (TMO) Traded Down due to Concerns Over Spending Cuts
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2025 investor letter.
Several Headwinds Pulled Down UnitedHealth Group’s (UNH) in Q2
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2025 investor letter.
Shift in Consumer Spending Challenged Target (TGT) in Q2
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2025 investor letter.
Clearbridge Large Cap Growth Strategy Sold Adobe (ADBE) Due to Concerns Over Market Penetration and Competition
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2025 investor letter.
Clearbridge Large Cap Growth Strategy Added Servicenow (NOW) to Elevate Select Growth Exposure
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2025 investor letter.
Should You be Confident in Netflix’s (NFLX) Long-Term Growth Potential?
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2025 investor letter.
Clearbridge Large Cap Growth Strategy Sold Its Stake in ICON Public Limited Company (ICLR)
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” second quarter 2025 investor letter.
Apple Inc. (AAPL): “What Do We Pay For Apple?” Wonders Jim Cramer
Apple Inc. (NASDAQ:AAPL) has become a regular feature of Cramer’s morning show over the past couple of months.
Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Alvotech (ALVO) Announces a Commercialization Agreement With Advanz Pharma
Alvotech (NASDAQ:ALVO) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating
Harrow, Inc. (NASDAQ:HROW) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)
Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, H.C.
H.C. Wainwright Maintains a Buy on Legend Biotech (LEGN) With a $75 Price Target
Legend Biotech Corporation (NASDAQ:LEGN) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 2, analyst Mitchell Kapoor from H.C.
Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating
CG Oncology, Inc. (NASDAQ:CGON) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Amicus Therapeutics (FOLD) Announces Approval for Pombiliti + Opfolda by Japan’s Ministry of Health, Labour and Welfare (MHLW)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 25, Amicus Therapeutics, Inc.
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT
Immunovant, Inc. (NASDAQ:IMVT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
POSCO Holdings to Build US Lithium Plant, Supports EV Supply Chain
POSCO Holdings Inc. (NYSE:PKX) is one of the best hot stocks to buy according to Wall Street analysts.
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts.
Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best hot stocks to buy according to Wall Street analysts.
Globalstar Begins Major C-3 Satellite System Ground Expansion with First Antenna Installation in Texas
Globalstar Inc. (NASDAQ:GSAT) is one of the best hot stocks to buy according to Wall Street analysts.
Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the best hot stocks to buy according to Wall Street analysts.
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer
UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best hot stocks to buy according to Wall Street analysts.
Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data
Prime Medicine Inc. (NASDAQ:PRME) is one of the best hot stocks to buy according to Wall Street analysts.
Hedge Fund Resource Center
